Arnatar Therapeutics
7 known investors
Arnatar develops a next-generation RNA discovery platform called DARGER that combines gene silencing and gene upregulation technologies for oligonucleotide therapeutics. The platform serves pharmaceutical researchers and biotechnology companies developing treatments for genetic disorders and other disease areas.
Founders & leadership
DX
Dr. Xuehai LiangFounder
DY
Dr. Yanfeng WangFounder & Chief Operating Officer
Investors · 7
3E Bioventures Capital✓ verifiedPalo Alto
F-Prime CapitalCambridge · $3M – $10M
Apricot Capitalreported · 2 sourcesShanghai
Eight Roads VenturesreportedMumbai · $5M – $30M
Gaorong VenturesreportedGeorge Town, Grand Cayman · $2.8M – $120M
Legend Starreported北京 · $425K – $112M
New Alliance CapitalreportedShanghai
Funding
SEC filings, press & company announcementsSource: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Arnatar Therapeutics do?
- Arnatar develops a next-generation RNA discovery platform called DARGER that combines gene silencing and gene upregulation technologies for oligonucleotide therapeutics. The platform serves pharmaceutical researchers and biotechnology companies developing treatments for genetic disorders and other disease areas.
- Who founded Arnatar Therapeutics?
- Arnatar Therapeutics was founded by Dr. Xuehai Liang, Dr. Yanfeng Wang.
- Who are Arnatar Therapeutics's investors?
- Arnatar Therapeutics's investors include 3E Bioventures Capital, F-Prime Capital, Apricot Capital, Eight Roads Ventures, Gaorong Ventures, Legend Star, New Alliance Capital.